Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2006;37:1271-1276
Published online before print April 6, 2006, doi: 10.1161/01.STR.0000217404.64352.d7
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/5/1271    most recent
01.STR.0000217404.64352.d7v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, J.
Right arrow Articles by Saavedra, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, J.
Right arrow Articles by Saavedra, J. M.
Right arrowPubmed/NCBI databases
*GEO DataSet*GEO Profiles
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Carotid endarterectomy
Right arrow Angioplasty and Stenting
Right arrow Cerebrovascular disease/stroke
Right arrow Carotid Stenosis

(Stroke. 2006;37:1271.)
© 2006 American Heart Association, Inc.


Original Contributions

AT1 Receptor Blockade Regulates the Local Angiotensin II System in Cerebral Microvessels From Spontaneously Hypertensive Rats

Jin Zhou, MD, PhD; Jaroslav Pavel, PhD; Miroslava Macova, PhD; Zu-Xi Yu, MD, PhD; Hans Imboden, PhD; Linna Ge, BSc; Tsuyoshi Nishioku, PhD; Jingtao Dou, MD, PhD; Elizabeth Delgiacco, BSc Juan M. Saavedra, MD

From the Section on Pharmacology (J.Z., J.P., M.M., L.G., T.N., J.D., E.D., J.M.S.), Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Md; Pathology Core (Z.-X.Y.), National Heart, Lung and Blood Institute, Bethesda, Md; and Institute of Cell Biology (H.I.), University of Bern, Bern, Switzerland.

Correspondence and reprint requests to Jin Zhou, MD, PhD, Section on Pharmacology, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA. E-mail jinzhou{at}mail.nih.gov

Background and Purpose— Blockade of angiotensin II AT1 receptors in cerebral microvessels protects against brain ischemia and inflammation. In this study, we tried to clarify the presence and regulation of the local renin-angiotensin system (RAS) in brain microvessels in hypertension.

Methods— Spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) controls were treated with an AT1 receptor antagonist (candesartan, 0.3 mg/kg per day) via subcutaneous osmotic minipumps for 4 weeks. The expression and localization of RAS components and the effect of AT1 receptor blockade were assessed by Affymetrix microarray, qRT-PCR, Western blots, immunohistochemistry and immunofluorescence.

Results— We found transcripts of most of RAS components in our microarray database, and confirmed their expression by qRT-PCR. Angiotensinogen (Aogen), angiotensin-converting enzyme (ACE) and AT1 receptors were localized to the endothelium. There was no evidence of AT2 receptor localization in the microvascular endothelium. In SHR, (pro)renin receptor mRNA and AT1 receptor mRNA and protein expression were higher, whereas Aogen, ACE mRNA and AT2 receptor mRNA and protein expression were lower than in WKY rats. Candesartan treatment increased Aogen, ACE and AT2 receptor in SHR, and increased ACE and decreased Aogen in WKY rats, without affecting the (pro)renin and AT1 receptors.

Conclusions— Increased (pro)renin and AT1 receptor expression in SHR substantiates the importance of the local RAS overdrive in the cerebrovascular pathophysiology in hypertension. AT1 receptor blockade and increased AT2 receptor stimulation after administration of candesartan may contribute to the protection against brain ischemia and inflammation.


Key Words: circulation • endothelial cells • hypertension • renin-angiotensin system




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
W. Kozak, A. Kozak, M. H. Johnson, H. F. Elewa, and S. C. Fagan
Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 773 - 782.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. A. Phipps, J. L. Wilkinson-Berka, and E. L. Fletcher
Retinal Dysfunction in Diabetic Ren-2 Rats Is Ameliorated by Treatment with Valsartan but Not Atenolol
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 927 - 934.
[Abstract] [Full Text] [PDF]